Status and phase
Conditions
Treatments
About
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The effects of therapeutic agents used in this trial on developing human fetus are unknown, and because of this, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation as outlined in criteria below:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
27 participants in 1 patient group
Loading...
Central trial contact
Marissa Folsom
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal